Perfil
David Dornan is Chief Scientific Officer at Whitehawk Therapeutics, Inc. since 2025.
Former roles include Chief Scientific Officer at Elevation Oncology, Inc. from 2022 to 2025, Senior Vice President-Research & Manufacturing at Bolt Biotherapeutics, Inc. from 2019 to 2022, and Director & Head-Oncology Research at Gilead Sciences, Inc. from 2012 to 2017.
Education includes a doctorate from the University Of Dundee and an undergraduate degree from the University of Strathclyde.
Cargos activos de David Dornan
| Empresas | Cargo | Inicio |
|---|---|---|
| WHITEHAWK THERAPEUTICS, INC. | Director Técnico/Científico/I+D | 18/02/2025 |
Antiguos cargos conocidos de David Dornan.
| Empresas | Cargo | Fin |
|---|---|---|
| ELEN ONCO | Director Técnico/Científico/I+D | 17/02/2025 |
| BOLT BIOTHERAPEUTICS, INC. | Director Técnico/Científico/I+D | 11/03/2022 |
| GILEAD SCIENCES, INC. | Director/Miembro de la Junta | 01/11/2017 |
Formación de David Dornan.
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 6 |
|---|---|
Gilead Sciences, Inc.
Gilead Sciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes therapeutic products and treatments for life threatening diseases | Health Technology |
University Of Dundee
University Of Dundee Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Strathclyde
University of Strathclyde Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage immuno-oncology company | Health Technology |
Elevation Oncology, Inc.
Elevation Oncology, Inc. Pharmaceuticals: MajorHealth Technology Develops elevating precision medicines for cancer treatment | Health Technology |
Aadi Bioscience, Inc.
Aadi Bioscience, Inc. BiotechnologyHealth Technology Develops mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases | Health Technology |
- Bolsa de valores
- Insiders
- David Dornan
















